Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
Transl Lung Cancer Res
.
2023 Aug 30;12(8):1826-1829.
doi: 10.21037/tlcr-23-288.
Epub 2023 Jul 28.
Authors
Lara Kujtan
1
,
Janakiraman Subramanian
2
Affiliations
1
Richard and Annette Bloch Cancer Center, University of Missouri at Kansas City, Kansas City, MO, USA.
2
Inova Schar Cancer Institute, Fairfax, VA, USA.
PMID:
37691875
PMCID:
PMC10483073
DOI:
10.21037/tlcr-23-288
No abstract available
Keywords:
Lung cancer; MET; epidermal growth factor receptor (EGFR); telisotuzumab vedotin.
Publication types
Editorial
Comment